Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 11/20 | 0.49 |
| ▸ | FNTB | P49356 | 11/20 | 0.49 |
| ▸ | RORC | P51449 | 6/20 | 0.42 |
| ▸ | PGGT1B | P53609 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13501480 | 0.94 | FNTA (0.44) | FNTAFNTBRORCPGGT1B | |
| SCHEMBL3973432 | 0.94 | FNTA (0.44) | FNTAFNTBRORC | |
| SCHEMBL3980315 | 0.93 | FNTA (0.43) | FNTAFNTBRORC | |
| SCHEMBL13501489 | 0.89 | FNTA (0.62) | FNTAFNTBPGGT1B | |
| SCHEMBL13501477 | 0.89 | FNTA (0.62) | FNTAFNTBPGGT1B | |
| SCHEMBL7668953 | 0.89 | FNTA (0.42) | FNTAFNTBRORCPGGT1B | |
| SCHEMBL3547921 | 0.85 | FNTA (0.58) | FNTAFNTBPGGT1B | |
| SCHEMBL6305116 | 0.83 | FNTA (0.48) | FNTAFNTBRORCPGGT1B | |
| SCHEMBL4382829 | 0.83 | FNTA (0.62) | FNTAFNTBRORCPGGT1B | |
| SCHEMBL5657230 | 0.81 | FNTA (0.43) | FNTAFNTB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2155197-A2 | TREATMENT OF LYSOSOMAL STORAGE DISEASES | Link Medicine Corporation (US) | 2010-02-24 | — | — | EP | claimed |
| EP-1809265-A4 | METHODS FOR THE TREATMENT OF SYNUCLEINOPATHIES | BRIGHAM & WOMENS HOSPITAL (US) | 2009-06-17 | — | — | EP | claimed |
| WO-2008112525-A2 | TREATMENT OF LYSOSOMAL STORAGE DISEASES | LINK MEDICINE CORPORATION (US) | 2008-09-18 | — | — | WO | claimed |
| EP-1809265-A2 | METHODS FOR THE TREATMENT OF SYNUCLEINOPATHIES | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2007-07-25 | — | — | EP | claimed |
| WO-2005089504-A2 | METHODS FOR THE TREATMENT OF SYNUCLEINOPATHIES | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2005-09-29 | — | — | WO | claimed |
| US-20030119843-A1 | 1,2-annelated quinoline derivatives | JANSSEN PHARMACEUTICA, N.V. | 2003-06-26 | — | — | US | claimed |
| EP-1140935-B1 | 1,2-ANNELATED QUINOLINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2003-05-14 | — | — | EP | claimed |
| US-6458800-B1 | 1,2-annelated quinoline derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2002-10-01 | — | — | US | claimed |
| US-8557847-B2 | Synergistic modulation of FLT3 kinase using a FLT3 inhibitor and a farnesyl transferase inhibitor | JANSSEN PHARMACEUTICA, N.V. (BE) | 2013-10-15 | — | — | US | disclosed |
| EP-1815247-B1 | THERAPEUTIC USE OF FARNESYLTRANSFERASE INHIBITORS AND METHODS OF MONITORING THE EFFICACY THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2013-02-20 | — | — | EP | disclosed |
| US-20120196766-A1 | Therapeutic Use of Farnesyltransferase Inhibitors and Methods of Monitoring the Efficacy Thereof | FOURIE ANNE MADELEINE (US) | 2012-08-02 | — | — | US | disclosed |
| US-20120108634-A1 | FARNESYL PROTEIN TRANSFERASE INHIBITOR COMBINATIONS WITH ANTIESTROGEN AGENTS | END DAVID WILLIAM (US) | 2012-05-03 | — | — | US | disclosed |
| EP-2362218-A2 | Methods of monitoring the efficacy of farnesyltransferase inhibitors | Janssen Pharmaceutica N.V. (BE) | 2011-08-31 | — | — | EP | disclosed |
| US-20110195419-A1 | THERAPEUTIC USE OF FARNESYLTRANSFERASE INHIBITORS AND METHODS OF MONITORING THE EFFICACY THEREOF | FOURIE ANNE MADELEINE | 2011-08-11 | — | — | US | disclosed |
| WO-2001064217-A2 | COMBINATIONS OF A FARNESYL PROTEIN TRANSFERASE INHIBITOR WITH NITROGEN MUSTARD OR NITROSOUREA ALKYLATING AGENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2001-09-07 | — | — | WO | disclosed |
| WO-2001064218-A2 | FARNESYL PROTEIN TRANSFERASE INHIBITOR COMBINATIONS | JANSSEN PHARMACEUTICA N.V. (BE) | 2001-09-07 | — | — | WO | disclosed |
| WO-2001064194-A2 | FARNESYL PROTEIN TRANSFERASE INHIBITOR COMBINATIONS WITH CAMPTOTHECIN COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2001-09-07 | — | — | WO | disclosed |
| WO-2001064196-A2 | FARNESYL PROTEIN TRANSFERASE INHIBITOR COMBINATIONS WITH VINCA ALKALOIDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2001-09-07 | — | — | WO | disclosed |
| WO-2001062234-A2 | DOSING REGIMEN | JANSSEN PHARMACEUTICA N.V. (BE) | 2001-08-30 | — | — | WO | disclosed |
| WO-2000039082-A2 | 1,2-ANNELATED QUINOLINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2000-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108634-A1 | FARNESYL PROTEIN TRANSFERASE INHIBITOR COMBINATIONS WITH ANTIESTROGEN AGENTS | FNTA, FNTB, PTAR1 | FNTA 1/4885FNTB 2/4885RORC 1742/4885 |
| US-20030119843-A1 | 1,2-annelated quinoline derivatives | NAT1, CYP7A1, CYP4A11 | FNTA 19/4885FNTB 27/4885RORC 60/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.